Novo-Nordisk Stock News & Updates
[WKN: 866931 | Symbol: NVO]
Strategic Milestone in Europe! Novo Nordisk Introduces the Weight Loss Pill to Great Britain!
Approval Success: Great Britain becomes the first European country to approve the Wegovy pill for...
Novo Nordisk Closes the gap in the GLP-1 Market! EU Approval for Higher-Dose Wegovy pen Received!
Comeback underway! Novo Nordisk is closing the gap with the Wegovy pill, surpassing Eli Lilly with...
US Markets Close at Record Highs – Trump Sees No Rush on Iran Deal – Trump’s Turn in Trauma Therapy – Microsoft Launches New Nvidia Desktop PCs – Alphabet Introduces New Waymo Model Ojai – Novo Nordisk Catches Up with Eli Lilly – Berkshire Acquires Taylor Morrison for $8.5 Billion – Revolution Medicines Achieves Breakthrough in Pancreatic Cancer – Yum! Brands Nears Sale of Pizza Hut
On Friday, May 29, 2026, US stock markets rose again and closed at record highs. The Dow Jones increased...
Diabetes Boom: These Stocks Will Benefit from the $190 Billion Market!
The global market for obesity and diabetes therapies is undergoing a structural reassessment: Investment...
Novo Nordisk has Been Underestimating the Market Potential for GLP-1 Pills! By 2030, Oral Medications Could Dominate Over a Third of the Market!
In our model portfolio, we invested €44.99 in Novo Nordisk on January 5, 2026. We followed this strategy...
Novo Nordisk: The end of the “horror year” & the starting signal for 2026!
The FDA approval of the Wegovy pill (Launch: January 2026!) is for me the absolute game changer. Anyone...
The new Week Starts with Signs of Recovery – Rate cut Fantasies, Ukraine Hopes, and Strong Travel Trends Support Investor Sentiment – Alphabet Drives Stock Market Rally – Hope for China Business Stabilizes NVIDIA – Tesla Confirms its own AI Chip Business – DAX Stabilizes, but ifo Data Weighs on Sentiments – Bayer Reports Study Success – Defense Stocks Decline
Market recovery underway The global stock markets are experiencing an upswing at the beginning of...
Novo Nordisk: When the Stock Market Overreacts
The stock market sometimes overreacts in both directions. With Novo Nordisk, we are currently witnessing...
A Necessary Cut at Novo Nordisk
The criticism of the current supervisory board appears plausible. Novo Nordisk has made significant mistakes...
Novo Nordisk acquires Zaltenibart from Omeros for up to $2.1 billion and strengthens its position in the treatment of rare blood and kidney diseases
Novo Nordisk (ii) acquires a promising drug from Omeros, which is being developed for the treatment of...
Novo Nordisk on the Rise! How the Danish Pharma Giant is Redefining the Global Weight Loss Boom!
What began as a medical innovation for diabetes treatment has developed into a global mass phenomenon....